Floatz logo

Berzosertib

Bilateral Breast Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Bilateral Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Sargramostim
Academic and Community Cancer Research United
Phase 2CCC
Cyclophosphamide
Academic and Community Cancer Research United
Phase 2CCC
Ixabepilone
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Berzosertib is also rated in:

small cell lung carcinomaActive
BBB
Indicative · Phase 2
73 / 100
View asset →
small cell carcinomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
fallopian tube carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →